➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6

No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw

• https://twitter.com/Yuz6Yusof/status/1400751549090041857

6. Rheum disease activity was stable with COVID vaccination. (RA, PsA, axSpA, SLE - total n = 597) 7/ LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0

I write more about this for @RheumNow - it’s powerful to know that AI can accurately tell the difference between RA, PsA, and healthy controls on the basis of the bony surface at MCP 2: https://t.co/ChDfihnW4f @LkasDer @maier_ak @FAU_Germany OP0145 #EULAR2021 (ping @DrCMcMaster) https://t.co/Pl7yxYfEqr

• Artificial intelligence brings clarity to early bony changes in inflammatory ar…
• https://twitter.com/drdavidliew/status/1400725921208803333

#OP0223 US disease activity and damage score for PsA - ~300 patients from 19 centres - 6 components for disease activity score & 5 for damage -->~90% variability explained --> weighted score -->many sites to scan --> evaluation as BL pred. for MDA #EULAR2021 @RheumNow https://t.co/5kC6YDQi8D

#OP0219 Population based matched medical record database study in PsA vs. non PsA from Israel: -> no differences in mortality -> BL predictors of death -higher risk: higher age, male sex, prior hospitalisation, prior psoriasis, comorbidties -lower: csDMARDs #EULAR2021 #RheumNow

tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. Deficiency of TYK2 gives less autoimmune diseases. @RheumNow @eular_org #EULAR2021 BMS Tyk Talk symposium https://t.co/knP9n0Qc0u

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu

• https://bit.ly/3vTTxdM

New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptoTate ) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more. https://t.co/AnHQGA8aKs https://t.co/yJbymc9csR

• https://bit.ly/3vTbF7B

HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3

• http://ow.ly/zQ7B50F3Gag

Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow